Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18281712 | 0.98 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2EPHX1CA12CA1 | |
| SCHEMBL8735981 | 0.98 | EPHX1 (0.43) | ALDH1A1SMN1; SMN2EPHX1CA12CA1 | |
| SCHEMBL28203322 | 0.80 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2EPHX1CA12CA1 | |
| Bromide SCHEMBL5466773 | 0.79 | SLC7A5 (0.46) | ALDH1A1SMN1; SMN2EPHX1DPP4 | |
| Bromide SCHEMBL5466774 | 0.79 | SLC7A5 (0.46) | ALDH1A1SMN1; SMN2EPHX1DPP4 | |
| SCHEMBL28236968 | 0.79 | IDO1 (0.34) | DPP4 | |
| SCHEMBL27962173 | 0.78 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2EPHX1CA12CA1 | |
| SCHEMBL7794337 | 0.78 | EPHX1 (0.43) | ALDH1A1SMN1; SMN2EPHX1CA12CA1 | |
| SCHEMBL28203211 | 0.78 | EPHX1 (0.43) | ALDH1A1SMN1; SMN2EPHX1CA12CA1 | |
| SCHEMBL27338949 | 0.78 | GAA (0.38) | ALDH1A1SMN1; SMN2EPHX1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981704-B2 | Decarboxylative conjugate additions and applications thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-05-14 | — | — | US | disclosed |
| US-20220002342-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2022-01-06 | — | — | US | disclosed |
| US-11136349-B2 | Decarboxylative conjugate additions and applications thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2021-10-05 | — | — | US | disclosed |
| US-20180179248-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2018-06-28 | — | — | US | disclosed |
| WO-2016196931-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2016-12-08 | — | — | WO | disclosed |
| EP-1896452-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-8044199-B2 | N-formyl hydroxylamines compounds | VICURON HOLDINGS LLC (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100063278-A1 | N-Formyl Hydroxylamines compounds | NOVARTIS AG (CH) | 2010-03-11 | — | — | US | disclosed |
| US-7615635-B2 | N-formyl hydroxylamines | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20090062537-A1 | N-Formyl Hydrozyamine Compounds | LEE KWANGHO | 2009-03-05 | — | — | US | disclosed |
| EP-1994027-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | Novartis AG (CH) | 2008-11-26 | — | — | EP | disclosed |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | VICURON HOLDINGS LLC | 2008-07-03 | — | — | US | disclosed |
| EP-1896452-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | Novartis Pharma AG. (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007106670-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| WO-2006127576-A2 | N - FORMYL HYDROXYLAMINE COMPOUNDS AS PDF INHIBITORS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
| US-5716973-A | ADMINISTERING DIFLUORO STATONE ANALOGS | MERRELL PHARMACEUTICALS INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5559140-A | VIRICIDES | MERRELL PHARMACEUTICALS INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0565631-B1 | ANTI-VIRAL COMPOUNDS | MERRELL PHARMA INC (US) | 1996-09-18 | — | — | EP | disclosed |
| EP-0565631-A1 | ANTI-VIRAL COMPOUNDS. | MERRELL DOW PHARMA (US) | 1993-10-20 | — | — | EP | disclosed |
| WO-1992012123-A1 | ANTI-VIRAL COMPOUNDS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179248-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | PTMS, DNPEP, QPCT | ALDH1A1 436/4885SMN1; SMN2 3507/4885EPHX1 3340/4885 |
| US-20220002342-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | PTMS, DNPEP, QPCT | ALDH1A1 436/4885SMN1; SMN2 3507/4885EPHX1 3340/4885 |
| US-20100063278-A1 | N-Formyl Hydroxylamines compounds | PDF, MMP2, HNMT | ALDH1A1 1461/4885SMN1; SMN2 4089/4885EPHX1 1858/4885 |
| US-11981704-B2 | Decarboxylative conjugate additions and applications thereof | PTMS, DNPEP, QPCT | ALDH1A1 436/4885SMN1; SMN2 3507/4885EPHX1 3340/4885 |
| US-11136349-B2 | Decarboxylative conjugate additions and applications thereof | PTMS, DNPEP, QPCT | ALDH1A1 436/4885SMN1; SMN2 3507/4885EPHX1 3340/4885 |
| US-20090062537-A1 | N-Formyl Hydrozyamine Compounds | PDF, HNMT, MMP2 | ALDH1A1 1755/4885SMN1; SMN2 3897/4885EPHX1 1652/4885 |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | PDF, MMP2, PEPD | ALDH1A1 1080/4885SMN1; SMN2 3632/4885EPHX1 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.